Hyperpigmentation

 

What is hyperpigmentation?

Hyperpigmentation is a darkening of the skin. This darkening of the skin may be generalized (happen all over) or localized, causing blotchy skin. It may be related to a phototoxic reaction in which areas exposed to light could have a golden brown or gray color.

What causes hyperpigmentation?

Some chemotherapy agents can cause hyperpigmentation. The cause of this side effect is currently unknown but may involve direct toxicity, stimulation of melanocytes (cells in skin responsible for skin color), and/or inflammation. Hyperpigmentation often appears 2 to 3 weeks after chemotherapy treatment begins and goes away as new skin cells replace the dead cells at approximately 10 to 12 weeks after treatment is over. However, this darkening may occasionally be permanent.

Chemotherapy drugs associated with temporary hyperpigmentation include:

  • Alkeran® (melphalan)
  • Myleran® (busulfan)
  • Cytoxan® (cyclophosphamide)
  • 5-FU (5-fluorouacil)
  • Adriamycin® (doxorubicin)
  • DaunoXome® (liposomal daunorubicin)
  • Blenoxane® (bleomycin)
  • Cosmegen® (dactinomycin)
  • BCNU (topical)

What are the symptoms of hyperpigmentation?

Hyperpigmentation from chemotherapy drugs may be generalized or it may occur in specific areas, such as:

  • Around the joints
  • Under the nails
  • In the mouth
  • Along the vein used to infuse chemotherapy
  • Under areas compressed by tape or dressings
  • In the hair (horizontal bands in light haired individuals)

How is hyperpigmentation treated?

At this time, there is no treatment for hyperpigmentation.

This content was last modified on May 01, 2008 .
Latest Cancer News
Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia

November 6, 2009 — Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.

Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence

November 6, 2009 — Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.

Alcohol May Reduce Risk of Thyroid Cancer

November 6, 2009 — Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.

Select news items provided by Reuters Health